Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.53 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.52 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.50 |
| ▸ | MMP13 | P45452 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | CMA1 | P23946 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15261978 | 0.91 | TAAR1 (0.54) | TAAR1ALDH1A1HTTSMN1; SMN2MTNR1A | |
| SCHEMBL2425450 | 0.88 | ALDH1A1 (0.56) | TAAR1ALDH1A1MDM2MTNR1AMTNR1B | |
| SCHEMBL19943588 | 0.85 | TAAR1 (0.68) | TAAR1ALDH1A1HTTSMN1; SMN2MTNR1A | |
| SCHEMBL346630 | 0.84 | SLC7A5 (0.46) | ALDH1A1MDM2 | |
| SCHEMBL2672357 | 0.83 | ALDH1A1 (0.60) | TAAR1ALDH1A1MDM2MTNR1AMTNR1B | |
| SCHEMBL6691644 | 0.82 | LDHA (0.50) | ALDH1A1MEN1KMT2A | |
| SCHEMBL6691798 | 0.81 | MAOB (0.62) | ALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL16509313 | 0.81 | TAAR1 (0.54) | TAAR1ALDH1A1HTTSMN1; SMN2MTNR1A | |
| SCHEMBL4596077 | 0.81 | TAAR1 (0.66) | TAAR1CYP1A2 | |
| SCHEMBL146611 | 0.81 | TAAR1 (0.66) | TAAR1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080221129-A1 | New compounds | BIOVITRUM AB (PUBL) (SE) | 2008-09-11 | — | — | US | disclosed |
| WO-2008003753-A1 | PYRAZOLO [1,5-A] PYRIMIDINE ANALOGS FOR USE AS INHIBITORS OF STEAROYL-COA DESATURASE (SCD) ACTIVITY | BIOVITRUM AB (PUBL) (SE) | 2008-01-10 | — | — | WO | disclosed |
| WO-2004096808-A1 | TRIAZINE COMPOUNDS AND THEIR USE | DE NOVO PHARMACEUTICALS LIMITED (GB) | 2004-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221129-A1 | New compounds | SCD, SCD5, FASN | TAAR1 3181/4885ALDH1A1 858/4885HTT 3278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.